医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Extension and Advancement of a Peptide Discovery Program

2014年10月03日 PM04:28
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587), announced today that one of the discovery programs initiated under the strategic alliance with Swiss-based Novartis has advanced into further optimization efforts, and will be extended and funded through an amendment to the original Strategic Alliance Agreement. PeptiDream identified macrocylic peptide candidates against an undisclosed target under the Macrocylic Peptide Drug Discovery Alliance, initiated in 2010 and extended in 2012. Candidates are undergoing optimization efforts in collaboration with Novartis, with PeptiDream using its PDPS system. The amendment provides additional research funding to cover additional PeptiDream resources focusing on the program’s optimization efforts and advancement.

[Comments from Patrick Reid, CSO, and Keiichi Masuya, COO, of PeptiDream Inc.]
“We are very excited with the program’s advancement. The additional funding will allow us to commit more resources toward the optimization efforts of this exciting program.”

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc
  • 瑞思迈首款最小接触型全脸CPAP面罩AirFit F30现已在美国和加拿大发售
  • AVITA Medical Announces First U.S. Sales of RECELL® System and Commencement of Commercial Shipping
  • PotNetwork Holdings, Inc.在注册成为SEC报告公司之后发布PCAOB经审计和审核的完整财务报表
  • PotNetwork Holdings, Inc.提交Form 10以成为美国证券交易委员会报告公司